TrueMark Investments LLC Acquires 3,807 Shares of Pfizer Inc. $PFE

TrueMark Investments LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 3.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 110,930 shares of the biopharmaceutical company’s stock after buying an additional 3,807 shares during the quarter. TrueMark Investments LLC’s holdings in Pfizer were worth $2,689,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 1.2%

PFE stock opened at $24.52 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.36. The business has a fifty day moving average price of $24.89 and a 200-day moving average price of $24.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $139.38 billion, a P/E ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.